(Q42107728)

16 October 2017

0 references

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease (English)

1 reference

constrictive pericarditis

16 October 2017

1 reference

M Townsend

1

1 reference

16 October 2017

D H MacIver

series ordinal

2

1 reference

16 October 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

16 October 2017

1 reference

16 October 2017

90

1 reference

16 October 2017

8

1 reference

16 October 2017

e47

1 reference

Pharmacological effects of cabergoline against parkinsonism

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1768376

PubMed Central

reference URL

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1768376

Low dose cabergoline induced interstitial pneumonitis.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1768376

PubMed Central

reference URL

17 August 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/15253989

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline

1 reference

https://pubmed.ncbi.nlm.nih.gov/15253989

PubMed

reference URL

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/HRT.2004.036236

1 reference

16 October 2017

1 reference

16 October 2017

PubMed publication ID

15253989

1 reference